The SSRI fluoxetine (FLX) is able to revert the brain oxidative damage by reducing lipid peroxidation at hippocampal level, also increasing the activity of antioxidant enzymes, such as superoxide dismutase (SOD) and catalase (CAT), in different animal models of depression (Chung et al., 2010; Moretti et al., 2012). The gene discussed is SOD1; the disease is depressive disorder.